Intrinsic Value of S&P & Nasdaq Contact Us

GABY Inc. GABLF OTC

Other OTC • Healthcare • Medical - Pharmaceuticals • CA • USD

SharesGrow Score
22/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

GABY Inc. (GABLF) .

Criteria proven by this page:

  • VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.

Overall SharesGrow Score: 21/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score
22/100
SG Score
View full scorecard →
VALUE
N/A
No coverage
FUTURE
N/A
No coverage
PAST
0/100
→ Income
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
MOAT
43/100
→ Income
~
GROWTH
58/100
→ Income
INCOME
10/100
→ Income

Valuation Snapshot — GABLF

Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.05
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.04
Book Value / Share$0.00
Revenue / Share$0.03
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year EPS (Diluted) Revenue Net Income Net Margin
2015 $-0.14 $379.64K $-2.8M -737.1%
2016 $-0.10 $578.87K $-3.04M -525.9%
2017 $-0.03 $757.48K $-2.99M -394.8%
2018 $-0.09 $1.1M $-5.67M -517.6%
2019 $-0.12 $7.56M $-17.45M -230.6%
2020 $-0.05 $3.19M $-10.97M -343.6%
2021 $-0.02 $25.94M $-9.75M -37.6%
2022 $-0.04 $21.77M $-29.25M -134.4%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message